Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

108.95 -1.62 (-1.47%)

Streaming Delayed Price Updated: 9:49 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

25 26 Next >

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗

March 23, 2023

Via Benzinga

Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

March 22, 2023

From Incyte

Via Business Wire

7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗

March 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.

Via InvestorPlace

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

March 18, 2023

From Incyte Corporation

Via Business Wire

Analyst Expectations for Incyte's Future ↗

March 07, 2023

Via Benzinga

Incyte's Return On Capital Employed Overview ↗

February 08, 2023

Via Benzinga

Analyst Ratings for Incyte ↗

February 08, 2023

Via Benzinga

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

March 18, 2023

From Incyte Corporation

Via Business Wire

Why Shares of MacroGenics Climbed Thursday ↗

March 16, 2023

The cancer-focused biotech delivered a strong earnings report.

Via The Motley Fool

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

March 14, 2023

From Incyte Corporation

Via Business Wire

Which S&P 500 Stocks Look Most Attractive Now? ↗

March 08, 2023

Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH.

Via Talk Markets

Earnings Outlook For Incyte ↗

February 06, 2023

Via Benzinga

2 Steady Stocks to Buy in a Recession ↗

February 03, 2023

Both companies are performing better than the broader market over the past year.

Via The Motley Fool

Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting

March 06, 2023

From Incyte

Via Business Wire

Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns ↗

March 06, 2023

Via Benzinga

Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis

March 03, 2023

From Incyte

Via Business Wire

Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents

February 24, 2023

From Incyte Corporation

Via Business Wire

Incyte to Present at Upcoming Investor Conference

February 16, 2023

From Incyte

Via Business Wire

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

February 10, 2023

From Incyte

Via Business Wire

Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone ↗

February 07, 2023

Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.

Via Investor's Business Daily

Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst ↗

February 07, 2023

Via Benzinga

Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs

February 07, 2023

From Incyte

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗

January 31, 2023

Via Benzinga

Incyte to Present at Upcoming Investor Conference

January 24, 2023

From Incyte

Via Business Wire

Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 19, 2023

On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.

Via Investor's Business Daily

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers ↗

January 18, 2023

From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock...

Via Talk Markets

Incyte to Report Fourth Quarter and Year-End 2022 Financial Results

January 17, 2023

From Incyte

Via Business Wire

Why These 7 Healthcare Stocks Could Soar in 2023 ↗

January 02, 2023

These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.

Via InvestorPlace

Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion ↗

December 31, 2022

China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by...

Via Talk Markets

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.